Let’s break down the Science of the Published article:
Who is Frontiers in Immunology?
“Our journals are led and peer-reviewed by editorial boards of over 100,000 top researchers. Covering more than 900 academic disciplines, we are one of the largest and highest-cited publishers in the world. To date, our freely accessible research articles have received over 1 billion views and downloads and 1.6 million citations.”
Title:
CCR5 Receptor Occupancy Analysis
- Just this part of the title means the receptor occupancy analysis is done.
What does it reveal?
- Increased (Peripheral Blood) CCR5+CD4+ T Cells *because of* Leronlimab
Two independent, methods calculated the Receptor Occupancy.
Weekly (injections of) Leronlimab led to increased CCR5+CD4+ T cells levels which lead to Suppression of the virus in the blood).
Both Receptor Occupancy methods show that the cells were protected from viral replication because of Leronlimab.
Maraviroc CCR5 RO is indirectly measured, and is taken by a percentage in their method of measuring only 25%. Some reports of 120% CCR5 RO shows the inaccuracy.
I believe that any trial with Long Hauler regarding the CCR5 (or using Maraviroc) will not be approved; (thus, not promotable for this indication) because no CCR5 RO test for that drug exists.
Basically, the RO for Maraviroc is unclear.
Therefore, any FUD from short posters about “amazing” results of a “trial” with Maraviroc won’t do them any good without an RO.
-Oh, how the tables have turned.-
In the LH study, we got the double blinded Receptor Occupancy assay data from 8 patients.
The CCR5 RO assay correctly identified individuals treated with Leronlimab versus placebo.
In summary, CytoDyn has created and validated two different methods of calculating CCR5 RO for Leronlimab.
If the FDA was asking for 1 Receptor Occupancy, it looks like we will be sending TWO formulas that work.
BULLISH and enjoy your weekend
Sorry for me being upset a while back. Many reached out, I think i become very irritable with LH and sifting through responses on some soft bashers here can be a lot.
Who is Frontiers in Immunology?
“Our journals are led and peer-reviewed by editorial boards of over 100,000 top researchers. Covering more than 900 academic disciplines, we are one of the largest and highest-cited publishers in the world. To date, our freely accessible research articles have received over 1 billion views and downloads and 1.6 million citations.”
Title:
CCR5 Receptor Occupancy Analysis
- Just this part of the title means the receptor occupancy analysis is done.
What does it reveal?
- Increased (Peripheral Blood) CCR5+CD4+ T Cells *because of* Leronlimab
Two independent, methods calculated the Receptor Occupancy.
Weekly (injections of) Leronlimab led to increased CCR5+CD4+ T cells levels which lead to Suppression of the virus in the blood).
Both Receptor Occupancy methods show that the cells were protected from viral replication because of Leronlimab.
Maraviroc CCR5 RO is indirectly measured, and is taken by a percentage in their method of measuring only 25%. Some reports of 120% CCR5 RO shows the inaccuracy.
I believe that any trial with Long Hauler regarding the CCR5 (or using Maraviroc) will not be approved; (thus, not promotable for this indication) because no CCR5 RO test for that drug exists.
Basically, the RO for Maraviroc is unclear.
Therefore, any FUD from short posters about “amazing” results of a “trial” with Maraviroc won’t do them any good without an RO.
-Oh, how the tables have turned.-
In the LH study, we got the double blinded Receptor Occupancy assay data from 8 patients.
The CCR5 RO assay correctly identified individuals treated with Leronlimab versus placebo.
In summary, CytoDyn has created and validated two different methods of calculating CCR5 RO for Leronlimab.
If the FDA was asking for 1 Receptor Occupancy, it looks like we will be sending TWO formulas that work.
BULLISH and enjoy your weekend
Sorry for me being upset a while back. Many reached out, I think i become very irritable with LH and sifting through responses on some soft bashers here can be a lot.
26
